Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis Source: Eur Respir J , 49 (4) 1600851; DOI: 10.1183/13993003.00851-2016 Year: 2017
Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017
Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Immunomodulatory properties of macrolide antibiotics in the treatment of bronchial sepsis involving P. aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 639s Year: 2004
The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Novel Pseudomonas aeruginosa scoring system to guide empiric anti-pseudomonal therapy in COPD patients with community-acquired pneumònia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020
Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005
The effect of erythromycin on the chronic lower airway infection by pseudomonas aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 640s Year: 2004
Pseudomonas aeruginosa drug susceptibility in patients hospitalized with COPD exacerbation and bronchiectasisSource: Eur Respir J 2001; 18: Suppl. 33, 541s Year: 2001
Long term treatment with azithromycin in chronic respiratory infections with pseudomonas aeruginosa Source: Eur Respir J 2006; 28: Suppl. 50, 558s Year: 2006
Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis}, Source: Eur Respir J 2012; 40: 1014-1023 Year: 2012
Pseudomonas aeruginosa and antibiotic resistance in acute exacerbations of COPD (AECOPD) Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa Year: 2009
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis Source: Eur Respir J 2002; 20: 658-664 Year: 2002
Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015
Daily versus weekly azithromycin in cystic fibrosis patients Source: Eur Respir J 2007; 30: 487-495 Year: 2007
Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients Source: Eur Respir J, 49 (5) 1601847; 10.1183/13993003.01847-2016 Year: 2017
Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia Source: Eur Respir J 2007; 29: 548-560 Year: 2007
Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015
Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014
Epidemiological-molecular study of colonization by pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 379s Year: 2002